nuclear receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Rebound A swing to a high level of glucose (sugar) in the blood after having a low level. See also: Somogyi effect. Receptors Regular insulin A type of insulin that is fast acting. Renal Related to the kidneys. Renal threshold When the blood is holding so much of a substance such as glucose (sugar) that the kidneys allow the excess to spill into the urine. This is also called "kidney threshold," "spilling point," and "leak point." Retina Retinopathy See also: Diabetic retinopathy. Risk factor Anything that raises the chance that a person will get a disease. With noninsulin-dependent diabetes, people have a greater risk of getting the disease if they weigh a lot more (20 percent or more) than they should.
All other European Union nations voted in favour or abstained: the Netherlands, which voted against a resolution in 2007, voted in favour, as did Finland and Norway, both of which had abstained in 2007, while the Czech Republic, which voted against the resolution in 2007, abstained. The two other states that voted against the resolution were Israel and the United States (both of which voted against in 2007), while as before China was absent for the vote, and Russia abstained. In June 2009, Belgium became the first country in the world to ban: "inert ammunition and armour that contains depleted uranium or any other industrially manufactured uranium." The move followed a unanimous parliamentary vote on the issue on 22 March 2007. The text of the 2007 law allowed for two years to pass until it came into force. In April 2009, the Belgian Senate voted unanimously to restrict investments by Belgian banks into the manufacturers of depleted uranium weapons. In September 2009, the Latin American Parliament passed a resolution calling for a regional moratorium on the use, production and procurement of uranium weapons. It also called on the Parlatino's members to work towards an international uranium weapons treaty. In November 2010 the Irish Senate passed a bill seeking to outlaw depleted uranium weapons, but it lapsed before approval by the Dáil.
Empagliflozin, sold under the brand name Jardiance ( JAR-dee-əns), among others, is an antidiabetic medication used to improve glucose control in people with type 2 diabetes and/or for patients with established heart failure with reduced ejection fraction (HFrEF). Studies have shown great benefits for heart failure (HF) outcomes and decreased hospitalisations. It is taken by mouth. Common side effects of empagliflozin include genital yeast infections and hypotension, particularly in patients with volume depletion. Other symptoms such as nausea and vomiting may occur and seem more pronounced in combination with metformin. Rare but serious adverse events, such as euglycemic diabetic ketoacidosis (DKA) which may present with hyperventilation, lethargy, or mental status changes have been reported but are infrequent in trials. Other serious but rare serious adverse events include Fournier's gangrene, a severe skin infection of the groin, and diabetic ketoacidosis that may occur even with normal blood glucose levels. Use during pregnancy or breastfeeding is not recommended. Empagliflozin is a SGLT2 inhibitor: a reversible inhibitor of the sodium glucose co-transporter-2 (SGLT-2). It reduces the kidney's glucose reabsorption and excretes the excess glucose through the urine, thus its place in the treatment of type two diabetes. It is dependent on blood glucose concentrations and the glomerular filtration rate of the kidney.
== Clinical significance == Some can be useful in measuring rates of metabolic processes (for example, 3,4-dihydroxyphenylacetic acid or 3-aminoisobutyrate). Because they can represent unnatural points of entry into natural metabolic pathways, some (such as AICA ribonucleotide) are of interest to researchers in developing new therapies.
Sources: en.wikipedia.org
== Defense mechanisms == Many small reptiles, such as snakes and lizards, that live on the ground or in the water are vulnerable to being preyed on by all kinds of carnivorous animals. Thus, avoidance is the most common form of defense in reptiles. At the first sign of danger, most snakes and lizards crawl away into the undergrowth, and turtles and crocodiles will plunge into water and sink out of sight.
=== Portrayals in film === He and his insulin discovery have also been depicted in various media formats, including comic books, a biography by Michael Bliss, and on television. The National Film Board of Canada produced a short film in 1958, The Quest. The 1988 television movie Glory Enough for All depicted the search for insulin by Banting and Best, with R. H. Thomson starring as Banting. Banting is also portrayed by Jason Priestley boarding his fatal flight in the 2006 historical drama Above and Beyond.
== Legal Issues == On 2 May 2018, he was charged with seven counts of drug trafficking and possession. He was released on $20,000 bail to appear in court at a later date. He was later cleared of trafficking but convicted of possession.
=== Indications === The lidocaine/prilocaine combination is indicated for dermal anaesthesia. Specifically it is applied to prevent pain associated with intravenous catheter insertion, blood sampling, superficial surgical procedures, and topical anaesthesia of leg ulcers for cleansing or debridement. Also, it can be used to numb the skin before tattooing as well as electrolysis and laser hair removal. It is also sometimes used in advance of injected local anaesthetics for minor surgery and biopsies. A topical spray consisting of an aerosol formulation of lidocaine and prilocaine was evaluated under the name PSD502 for use in treating premature ejaculation. The spray is applied on the penile skin prior to intercourse. While this formulation was not approved by the FDA, a similar product, Promescent, is available over-the-counter in the U.S.
An official independence referendum happens later in December August 25: Belarus declares independence from the Soviet Union. August 27: Moldova declares independence from the Soviet Union. August 31: Uzbekistan and Kyrgyzstan declare independence from the Soviet Union. September: 1991 Zaire unrest occurred. September 7: Macedonia holds an independence referendum with a majority voting in favor of independence. September 9: Tajikistan declares independence from the Soviet Union. September 21: Armenia holds an independence referendum with a majority voting for independence from the Soviet Union despite declaring independence in August 1990. October 26: Turkmenistan holds an independence referendum with a majority voting for independence from the Soviet Union. October 27: Turkmenistan declares its independence from the Soviet Union. October 31: The Djiboutian Civil War begins. November 1: Chechnya declares sovereignty. November 12: The Indonesian Army massacred at least 250 East Timorese pro-independence protesters during the Indonesian occupation of East Timor. December 1: Ukraine holds an independence referendum with a majority voting in favor of independence. December 16: Kazakhstan declares its full independence from the Soviet Union. December 22: The Georgian Civil War begins. December 25: Mikhail Gorbachev resigns as President of the USSR. The flag of the Soviet Union is lowered for the last time over the Kremlin and is later replaced by the Russian flag. Also that day U.S. President George H. W.
Sources: en.wikipedia.org
== External links == Professor Wickramasinghe's profile at the University of Buckingham Interviews Publication List Chandra Wickramasinghe@ Astrophysics Data System Prof Chandra Wickramasinghe in conversation with artist and poet, Himali Singh Soin, podcast, 2022
== Expert reviews of the evidence == Letby has maintained that she is innocent of the offences for which she was convicted. Following the trials, a number of medical, statistical and other scientific experts have criticised the prosecution's evidence. The defence have been criticised for failing to call any of their own expert witnesses at trial. In 2025, a panel of experts convened by neonatologist Shoo Lee, provided with the infants' records and other trial evidence by Letby's legal representatives, published an assessment of the cases which presented alternative explanations for all of the deaths and collapses. The infants' families and the prosecution's lead expert witness have disputed these findings. The Court of Appeal has previously rejected challenges to the safety of the convictions.
=== ADHD === Attention deficit hyperactivity disorder is a neurodevelopmental condition involving problems with attention, hyperactivity, and impulsiveness. It is most commonly treated using stimulant drugs such as methylphenidate (Ritalin), whose primary effect is to increase dopamine levels in the brain, but drugs in this group also generally increase brain levels of norepinephrine, and it has been difficult to determine whether these actions are involved in their clinical value. There is also substantial evidence that many people with ADHD show biomarkers involving altered norepinephrine processing. Several drugs whose primary effects are on norepinephrine, including guanfacine, clonidine, and atomoxetine, have been tried as treatments for ADHD, and found to have effects comparable to those of stimulants.
Nuclear emulsions are similar to photographic emulsions, except that they are used in particle physics to detect high-energy elementary particles. Whilst an emulsion roughly corresponds to a mixture of at least two immiscible liquids mixed together, by contrast emulsification is the process of dispersing two or more immiscible liquids together through the use of an emulsifier (e.g., lecithin in a mixture of oil and water). Nanoemulsification is the process of emulsification in the nanoscale. A nanoemulsion is a particular kind of emulsion, with droplet sizes on the order of 100 nm.
== Pathovars == Following ribotype analysis, incorporation of several pathovars of P. syringae into other species was proposed (see P. amygdali, 'P. tomato', P. coronafaciens, P. avellanae, 'P. helianthi', P. tremae, P. cannabina, and P. viridiflava). According to this schema, the remaining pathovars are:
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.